Angelini Announces close of acquisition of two Sanofi consumer healthcare (CHC) products in Germany and Austria

Rome, 29 August 2019

Angelini Pharma announces the acquisition of two Sanofi CHC brands in Germany and Austria for a total of € 47 M.

The acquired products include BoxaGrippal® (ibuprofen/pseudoephedrine) a Pharmacy-Only OTC brand that provides effective temporary relief from a range of Common Cold & Flu symptoms, and Heumann a well-established Pharmacy-Only OTC herbal medicinal group of teas for the treatment of diverse conditions, including mild bladder and kidney sicknesses, cough and stomach-bowel ache.

Boxagrippal® was launched by Boehringer Ingelheim in 2013 and today top ranks in its category (#4 in Germany and #3 in Austria).

Heumann Teas have a strong heritage of more than 60 years in herbal medicinal preparations.

Those acquired products support Angelini Pharma reinforcing both its OTC business and consolidating its presence in Germany and Austria. Boxagrippal® and Heumann Teas will add to the main brand Tantum®, successfully marketed in the two above mentioned countries since many years.

About Angelini

Angelini is a Private Company established in Italy in 1919 that employs approximately 6,000 people. Angelini Pharma is the pharmaceutical Company of the Angelini Group representing more than 50% of its annual €1.6 billion revenues.

Angelini Pharma is an “integrated pharmaceutical company” with extensive R&D programs, world-class manufacturing and marketing of active ingredients and branded drugs. Angelini is committed to help patients fighting diseases with a focus on Mental health, Pain and Consumer Health.

Angelini products are marketed in about 70 countries. The company operates directly in 15 countries employing about 3,000 people.